Not a healthcare professional? Visit our Public site

report_adverse_events REPORT ADVERSE EVENT Login Register notification bell

Placeholder

    Contact us REQUEST A REPRESENTATIVE
    Rate us RATE YOUR EXPERIENCE

    Your browser is not supported.

    To view this content, please use one of the following browsers:

    • Microsoft Edge
    • Chrome
    • Safari
    • Home
    • Events Calendar
    • Home
    • Events Calendar

    Events Calendar

    Upcoming Events

    Upcoming events relevant to the therapy areas of our treatments:
    ▼Rezzayo (rezafungin) click for GB or NI prescribing information 
    Flutiform (fluticasone propionate / formoterol) click for prescribing information
    webinar

    English

    02:15

    Webinar
    Webinar

    Introducing ▼REZZAYO® rezafungin, the first once weekly echinocandin....

    Introducing REZZAYO® (rezafungin), the first once weekly echinocandin indicated for the treatment of invasive candidiasis in adults. Consideration should be given to official guidance on the appropriate use of antifungal agents.1 With a renowned faculty of Professor Oliver Cornely, Professor Tihana Bicanic and Professor Matteo Bassetti.

     

    References

    1. REZZAYO® (rezafungin). Summary of Product Characteristics. Napp 2024.

     

    Agenda

    19:00-20:00 BST

    • Key challenges in the management of invasive candidiasis​
    • The data from the REZZAYO® clinical trial programme​
    • The potential benefits of REZZAYO® in the ICU, ward and for the outpatient
    • Q&A
       

    Antifungal

    Professor Tihana Bicanic, Professor Oliver Cornely, Professor Matteo Bassetti

    I'M INTERESTED
     

    Recordings from Past Events

    Load More

    Reporting adverse events

    Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

    Adverse events should also be reported to Napp Pharmaceuticals Limited on 01223 424444 or drugsafetyUKandROI@mundipharma.com.